SCHEMBL3026744

SCHEMBL3026744

CCOC(=O)CCc1ccc(NC(=O)c2cc([Si](C)(C)C)cc([Si](C)(C)C)c2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.50
CYP4A11 Q02928 1/20 0.50
SMN1; SMN2 Q16637 4/20 0.48
LMNA P02545 2/20 0.48
MAPT P10636 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.46
MITF O75030 1/20 0.45
MEN1 O00255 1/20 0.45
HTT P42858 1/20 0.45
KMT2A Q03164 1/20 0.45
NAMPT P43490 1/20 0.45
CYP4Z1 Q86W10 1/20 0.44
CCR5 P51681 2/20 0.44
PDE3B Q13370 1/20 0.43
PDE3A Q14432 1/20 0.43
P2RY12 Q9H244 1/20 0.43
NR1H4 Q96RI1 1/20 0.43
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3018673 0.84 NR1H4 (0.60) MEN1KMT2ACCR5NR1H4
SCHEMBL3034258 0.78 CA12 (0.51) SMN1; SMN2MAPTMEN1KMT2AP2RY12
SCHEMBL3034256 0.78 CA12 (0.51) SMN1; SMN2MAPTMEN1KMT2AP2RY12
SCHEMBL6984766 0.76 CYP4F2 (0.64) CYP4F2CYP4A11SMN1; SMN2LMNAMAPT
SCHEMBL7379154 0.76 PLAU (0.55) CYP4F2CYP4A11SMN1; SMN2LMNAMAPT
SCHEMBL7377053 0.76 KMT2A (0.53) CYP4F2CYP4A11SMN1; SMN2LMNAMAPT
SCHEMBL1747191 0.75 HDAC1 (0.69) SMN1; SMN2LMNAMAPTL3MBTL1MEN1
SCHEMBL27509756 0.75 CYP4F2 (0.62) CYP4F2CYP4A11SMN1; SMN2LMNAMAPT
Hydrochloric Acid SCHEMBL9235167 0.75 MEN1 (0.52) CYP4F2CYP4A11SMN1; SMN2LMNAMAPT
SCHEMBL3131697 0.74 KDM4E (0.53) SMN1; SMN2LMNAMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7855300-B2 Bis(trimethylsilyl)phenyl compound or salt thereof, and use thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2010-12-21 US disclosed
US-20100210591-A1 BIS(TRIMETHYLSILYL)PHENYL COMPOUND OR SALT THEREOF, AND USE THEREOF TAIHO PHARMACEUTICAL CO., LTD. (JP) 2010-08-19 US disclosed
EP-2202235-A1 BIS(TRIMETHYLSILYL)PHENYL COMPOUND OR SALT THEREOF, AND USE THEREOF Taiho Pharmaceutical Co., Ltd. (JP) 2010-06-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210591-A1 BIS(TRIMETHYLSILYL)PHENYL COMPOUND OR SALT THEREOF, AND USE THEREOF RARA, RARB, RXRA CYP4F2 2981/4885CYP4A11 655/4885SMN1; SMN2 2210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.